Evidence map›Paper›PMID 38998669›Full record

ReviewNanomaterials (Basel, Switzerland)2024

Transition Metal Oxide Nanomaterials: New Weapons to Boost Anti-Tumor Immunity Cycle.

Wanyi Liu, Xueru Song, Qiong Jiang, Wenqi Guo, Jiaqi Liu, Xiaoyuan Chu, Zengjie Lei

Abstract readReview
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Periodic Table of Immunomodulatory Elements and Derived Two-Dimensional Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wanyi LiuDepartment of Medical Oncology, Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing 210000, China.ORCID 0009-0001-6915-090X
Xueru SongDepartment of Medical Oncology, Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing 210000, China.ORCID 0000-0002-2760-8441
Qiong JiangDepartment of Gastroenterology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210023, China.
Wenqi GuoDepartment of Medical Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210000, China.ORCID 0009-0001-2749-1415
Jiaqi LiuDepartment of Medical Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210000, China.ORCID 0009-0000-4826-584X
Xiaoyuan ChuDepartment of Medical Oncology, Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing 210000, China.
Zengjie LeiDepartment of Medical Oncology, Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing 210000, China.ORCID 0000-0001-8961-3214

Funding

China Postdoctoral Science Foundation 2020M670090ZXJiangsu Funding Program for Excellent Postdoctoral Talent 2023ZB381National Natural Science Foundation of China 82072725
6 · The paper itself

Abstract

Semiconductor nanomaterials have emerged as a significant factor in the advancement of tumor immunotherapy. This review discusses the potential of transition metal oxide (TMO) nanomaterials in the realm of anti-tumor immune modulation. These binary inorganic semiconductor compounds possess high electron mobility, extended ductility, and strong stability. Apart from being primary thermistor materials, they also serve as potent agents in enhancing the anti-tumor immunity cycle. The diverse metal oxidation states of TMOs result in a range of electronic properties, from metallicity to wide-bandgap insulating behavior. Notably, titanium oxide, manganese oxide, iron oxide, zinc oxide, and copper oxide have garnered interest due to their presence in tumor tissues and potential therapeutic implications. These nanoparticles (NPs) kickstart the tumor immunity cycle by inducing immunogenic cell death (ICD), prompting the release of ICD and tumor-associated antigens (TAAs) and working in conjunction with various therapies to trigger dendritic cell (DC) maturation, T cell response, and infiltration. Furthermore, they can alter the tumor microenvironment (TME) by reprogramming immunosuppressive tumor-associated macrophages into an inflammatory state, thereby impeding tumor growth. This review aims to bring attention to the research community regarding the diversity and significance of TMOs in the tumor immunity cycle, while also underscoring the potential and challenges associated with using TMOs in tumor immunotherapy.

Indexed as

transition metal oxides (TMOs)tumor immunity cycletumor immunotherapywide-bandgap semiconductor

Identifiers

PMID38998669
PMCPMC11243522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.